

Instructions to Authors

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form.

All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. The Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society must be followed.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC - IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (link to: <http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iar-anticancer.org (mail to: journals@iar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
John G. Delinassios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, GR-19014 Kapandriti, Attiki, GREECE.

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS

www.cgp-iiarjournals.com

Print ISSN: 1109-6535
Online ISSN: 1790-6245
VOL. 1 (2004) - VOL. 9 (2012)



General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our websites www.cgp-journals.com; www.iiar-anticancer.org and www.iiarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. e-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Free specimen copies of CGP are available on request.

A Selection of Recent Papers

KRAS Mutation is Associated with Elevated Myeloblastin Activity in Human Lung Adenocarcinoma. T. WIEDL, S. COLLAUD, S. HILLINGER, S. ARNI, C. BURGESS, W. KROLL, P. SCHRAML, A. SOLTERMANN, H. MOCH, W. WEDER (*Zurich, Switzerland; Cambridge, MA, USA*)

Early detection of Ovarian Cancer in Pre-diagnosis Samples Using CA125 and MALDI MS Peaks. J.F. TIMMS *et al* (*London; Reading, UK*)

Decoding Differentially Regulated Epithelial and Stromal Pathways in Colorectal Cancer. M. ABBA, S. LAUFS, M. AGHAJANY, B. KORN, A. BENNER, H. ALLGAYER (*Heidelberg, Germany*)

New Gene Groups Associated with Dissimilar Osteoblastic Differentiation Are Linked to Osteosarcomagenesis. F. LUK, Y. YU, H.- T. DONG, W.R. WALSH, J.- L. YANG (*Sydney, NSW, Australia*)

Small Molecule Inhibition of Cytoskeletal Dynamics in Melanoma Tumors Results in Altered Transcriptional Expression Patterns of Key Genes Involved in Tumor Initiation and Progression. C. SPENCER, J. MONTALVO, S.R. MCLAUGHLIN, B.A. BRYAN (*Worcester, MA, USA*)

Gene Expression Profile Can Predict Pathological Response to Preoperative Chemoradiotherapy in Rectal Cancer. M. NISHIOKA, M. SHIMADA, N. KURITA, T. IWATA, S. MORIMOTO, K. YOSHIKAWA, J. HIGASHIJIMA, T. MIYATANI (*Tokushima, Japan*)

Gene Expression Profiling and its Utility in Prediction of Local Relapse after Breast-conserving Therapy in Early Breast Cancer. R. SABATIER, P. FINETTI, N. CERVERA, A. TALLET, M. BENCHALAL, G. HOUVENAEGHEL, J. JACQUEMIER, D. BIRNBAUM, F. BERTUCCI (*Marseille; Rennes, France*)

Restoration of Senescence in Breast and Ovarian Cancer Cells Following the Transfer of the YAC Carrying SEN6A Gene Located at 6q16.3. N.S. RANE, A.K. SANDHU, V.S. ZHAWAR, G. KAUR, N.C. POPESCU, R.P. KANDPAL, M. JHANWAR-UNIYAL, R.S. ATHWAL (*Philadelphia, PA; Bethesda, MD; Pomona, CA; Valhalla, NY, USA*)

Therapy-, Gender- and Race- specific microRNA Markers, Target Genes and Networks Related to Glioblastoma Recurrence and Survival. K.R. DELFINO, N.V.L. SERÃO, B.R. SOUTHEY, S.L. RODRIGUEZ- ZAS (*Urbana, IL, USA*)

Differential Splicing Generates New Transmembrane Receptor and Extracellular Matrix-related Targets for Antibody-based Therapy of Cancer (Review). U.H. WEIDLE, D. MAISEL, S. KLOSTERMANN, E.H. WEISS, M. SCHMITT (*Penzberg; Planegg-Martinsried; Munich, Germany*)

The Cancer Biomarker Osteopontin: Combination with Other Markers (Review). G.F. WEBER (*Cincinnati, OH, USA*)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma (Review). T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

TGF- β 1 Interactome: Metastasis and Beyond (Review). M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO- MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAL, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (*Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA*)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer (Review). N. VALERI, C.M. CROCE, M. FABBRI (*Columbus, OH, USA; Ferrara; Meldola, Italy*)

The Continuing Search for Predisposing Colorectal Cancer Variants (Review). S. PICELLI, S. VON HOLST, P. WESSENDORF (*Stockholm, Sweden*)

The Cytotoxic Protein Can Induce Autophagocytosis in Addition to Apoptosis in MCF-7 Human Breast Cancer Cells. G.-T. YIANG, Y.-L. YU, P.-L. CHOU, H.-F. TSAI, L.-A. CHEN, Y.H. CHEN, K.-J. SU, J.-J. WANG, D.-T. BAU, C.-W. WEI (<i>Hualien; New Taipei City; Taichung; Taipei, Taiwan, ROC; Atlanta, GA, USA</i>)	403
Biological Activity of SE-10, Granulated Powder of <i>Sasa senanensis</i> Rehder Leaf Extract. H. SAKAGAMI, T. MATSUTA, K. SATOH, S. OHTSUKI, C. SHIMADA, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, Y. MORITA, A. OHKUBO, T. TSUDA, K. SUNAGA, J. MAKI, T. SUGIURA, M. KITAJIMA, H. OIZUMI, T. OIZUMI (<i>Saitama; Tokyo; Kanagawa; Matsuyama, Japan</i>)	411
Efficacy of a Proapoptotic Peptide towards Cancer Cells. C.E. JÄKEL, K. MESCHENMOSER, Y. KIM, H. WEIHER, I.G.H. SCHMIDT-WOLF (<i>Rheinbach; Bonn, Germany</i>)	419
Retinal and Renal Vascular Permeability Changes Caused by Stem Cell Stimulation in Alloxan-induced Diabetic Rats, Measured by Extravasation of Fluorescein. Z. DOCZI-KERESZTESI, J. JUNG, I. KISS, T. MEZEI, L. SZABO, I. EMBER (<i>Targu Mures, Romania; Pecs; Eger, Hungary</i>).....	427
Evaluation of Genotoxicity and Subclinical Toxicity of <i>Agaricus blazei</i> Murrill in the Ames Test and in Histopathological and Biochemical Analysis. J.-B. CHANG, H.-F. LU, N.-C. LIAO, C.-S. LEE, M.-Y. YEH, C.-M. LIU, M.-T. CHUNG, A. MAN-KUAN, J.-J. LIN, M.-F. WU, J.-G. CHUNG (<i>Taipei; Hsinchu; New Taipei; Taichung, Taiwan, ROC</i>)	437
Venous Graft for Reconstruction of Neoplastic and Post-traumatic Eyelid Defects. G.M. TOMASSINI, V. ANSIDEI, A.L. RICCI, C. CAGINI, F. CENCETTI, S. SIMONETTI, P. COVARELLI (<i>Perugia, Italy</i>)	447
<i>Clinical Studies</i>	
Nasolabial Cyst: Case Report with Respect to Immunohistochemical Findings. R.E. FRIEDRICH, H.A. SCHEUER, A.T. ASSAF, J. ZUSTIN (<i>Hamburg, Germany</i>)	453
Angiomyolipomatous Hamartoma of the Inguinal Lymph Node – Report of Two Cases and Literature Review. T. DŽOMBETA, M. FRANČINA, K. MATKOVIĆ, I. MARKOVIĆ, Z. JUKIĆ, C. LEŽ, B. KRUXLIN (<i>Zagreb; Nova Gradixka; Zabok, Croatia</i>).....	459
Local Tolerance of a Sublingual Nicotine Tablet, an Open Single-centre Study. L. SAND, A.-K. LEKERUD, M. WALLSTRÖM, J.M. HIRSCH (<i>Uppsala; Gothenburg, Sweden</i>).....	463
An Antibiotic Care Bundle Approach Based on Results of Rapid Molecular Screening for Nasal Carriage of Methicillin-resistant <i>Staphylococcus aureus</i> in the Intensive Care Unit. P. STANO, M. AVOLIO, R. DE ROSA, M.L. MODOLO, S.M.M. BASSO, F. LUMACHI, A. CAMPORESE (<i>Pordenone; Padova, Italy</i>)	469
Heterogeneity of DNA Ploidy in Endometrial Carcinoma: Comparison of Different Tissue Samples Obtained during Diagnosis and Treatment. P. LIBALOVA, Z. VERNEROVA, L. HUBICKOVA-HERINGOVA, D. PINTEROVA, K. KOLOSTOVA, V. BOBEK, K. TIKOVSKY, D. HOUSA, M. KUBECOVA, L. PECEN, B. SVOBODA (<i>Prague, Czech Republic; Dyfed, UK</i>).....	473
Influence of Gender on Mortality and Need for Extracorporeal Membrane Oxygenation in Neonates with Congenital Diaphragmatic Hernia. S. BERLIT, A. HORNEMANN, T. SCHAIBLE, W. NEFF, R. SCHAFFELDER, J. SIEMER, M. SÜTTERLIN, S. KEHL (<i>Mannheim, Germany</i>).....	481
Reviews (pages 381, 395)	